Clinical trial · Observational
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
NCT03687294CI-TRIAL-00046070unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Neoplasm of Salivary Gland | Benign Salivary Gland Neoplasm | ALIAS | 0.90 |
| Malignant Neoplasm of Salivary Gland | Malignant Salivary Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| enzyme linked immunosorbent assay (ELISA) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group I
- description
- patients suffering from malignant salivary gland tumors.
- interventionNames
- Device: enzyme linked immunosorbent assay (ELISA)
- label
- Group II
- description
- patients suffering from benign salivary gland tumors.
- interventionNames
- Device: enzyme linked immunosorbent assay (ELISA)
Primary outcomes (1)
- measure
- Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
- timeFrame
- two years
- description
- Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: . * Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I * Benign tumors will be recruited in group II. Exclusion Criteria: * Subjects taking any drugs inducing any changes that could affect the salivary glands. * Pregnant females. * Subjects having any allergies, infectious or autoimmune diseases. * Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.
References
Publications (0)
Data not yet available
No reference posted for this study.